Navigation Links
Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
Date:9/17/2008

- ORACLE MS Phase III Trial Will Assess Effectiveness of Cladribine Tablets in Preventing Conversion to Definite Multiple Sclerosis in Addition to the

Fully Enrolled Phase III Pivotal Trial -

- the CLARITY Study -

- for Treatment of Relapsing Forms of Multiple Sclerosis

GENEVA, Sept. 18 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the initiation of a Phase III trial to evaluate the therapeutic effects of its proprietary oral formulation of Cladribine (Cladribine tablets) in patients at risk of developing multiple sclerosis (MS).

The trial, called ORACLE MS (Oral Cladribine in Early MS) will evaluate the safety and efficacy of two dosage regimens of Cladribine tablets versus placebo in the treatment of patients who have experienced a first clinical event suggestive of MS. Cladribine tablets are currently also being evaluated in a fully enrolled Phase III pivotal trial - the CLARITY(1) study -- for treatment of relapsing forms of MS. As announced in January 2007, CLARITY was the first pivotal trial among all Phase III oral compounds in development for MS to complete enrollment. Cladribine tablets have been granted a fast track designation by the US Food and Drug Administration.

"There is increasing evidence supporting the initiation of treatment with a disease-modifying drug in patients who have experienced a first clinical event suggestive of multiple sclerosis, an initial stage of the disease when clinical manifestations are not necessarily pronounced but where the potential exists for irreversible neurological damage to take place," said Dr. Thomas Leist, Associate Professor of Neurology and Director of the Comprehensive MS Center at Thomas Jefferson University, Philadelphia, PA, and an investigator in the ORACLE MS study. "The ORACLE MS study will evaluate the effectiveness and safety of Cladribine tablets in preventing conversion to
'/>"/>

SOURCE Merck Serono International S A
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
4. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
5. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
6. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
7. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
8. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
9. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
10. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
11. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... The acute coronary syndrome (ACS) therapeutics market ... of generics. While generic ACS drugs currently lead in ... to increase to more than 60 percent of the ... novel pipeline products between 2015 and 2019. The US ... of revenues, driven primarily by incidence rates of ACS ...
(Date:9/1/2015)... 1, 2015  Amgen (NASDAQ: AMGN ) ... the areas of Alzheimer,s disease and migraine. The ... by teaming up with Novartis on a differentiated ... genetically predisposed individuals at risk of developing Alzheimer,s ... the commercialization of its migraine programs in the ...
(Date:9/1/2015)... 1, 2015 Ardelyx, Inc. (NASDAQ: ... gastrointestinal and cardio-renal diseases, today announced that Sanofi ... and license agreement for Ardelyx,s portfolio of NaP2b ... payment associated with termination and the return of ... Sanofi entered into an option and license agreement ...
Breaking Medicine Technology:Branded Acute Coronary Syndrome Therapies to Grab Market Share from Generic Drugs Globally 2Branded Acute Coronary Syndrome Therapies to Grab Market Share from Generic Drugs Globally 3Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 2Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 3Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 4Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 5Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 6Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 7Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 8Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 9Ardelyx Regains NaP2b Program from Sanofi 2Ardelyx Regains NaP2b Program from Sanofi 3
... the body temperatures of newborns with temporal artery ... according to a cross-sectional study recently published in ... are necessary when measuring neonate temperatures. ... Sanglah Hospital within the Neonatology Division of the ...
... Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR ) announced ... Index(R) (Nasdaq: NBI) in anticipation of the company,s pending acquisition ... to the market,s opening. This customary NASDAQ ... a company,s anticipated merger or acquisition in order to allow ...
Cached Medicine Technology:New Study Finds Temporal Artery Thermometry Equivalent to Rectal Thermometry 2
(Date:9/2/2015)... IL (PRWEB) , ... September 02, 2015 , ... ... off ahead of Breast Cancer Awareness Month (BCAM), Bright Pink, a national non-profit ... young women, will launch Act On Facts, a campaign to educate women to ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... hundreds of thousands of plastic surgeries conducted each year on teenagers, quoting a ... the growing numbers. Beverly Hills-based plastic surgeon Payam Jarrah-Nejad, M.D., F.I.C.S., F.A.C.S., known ...
(Date:9/1/2015)... ... September 01, 2015 , ... The Capillus82™ ... treatment of androgenic alopecia in adults, announces Miami-based medical device manufacturer, Capillus, LLC. ... also demonstrating its safety when used at home to combat hair loss. ...
(Date:9/1/2015)... ... 01, 2015 , ... ProRehab Physical Therapy , Louisville’s ... with Apex Physical Therapy (Apex) is official as of August 26, ... and empathetic care to local residents from their combined eight locations throughout Louisville. ...
(Date:9/1/2015)... ... September 01, 2015 , ... From Aug. 17-21, Calvary Hospital ... from ages 6-18. Calvary’s Camp Compass® has taken place at Kingsborough Community College in ... counselors, some of whom work for Calvary, and two junior counselors who were campers ...
Breaking Medicine News(10 mins):Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 3Health News:Teen Plastic Surgery Article Understates the Most Important Realities of Procedures on Young People, Notes Dr. J 2Health News:Capillus82™ Laser Therapy Cap Receives FDA Clearance for Treatment of Hair Loss 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3
... Fla. Like rock stars of the rodent world, the ... most attention from the ladies, a University of Florida study ... vocal trills, and a bravura performance attracts more interest from ... the journal Animal Behaviour by doctoral candidate Bret ...
... area known for its high concentration of asbestos-contaminated dust, have ... regions where asbestos pollution levels are lower. This has been ... Ben-Shlomo and Dr. Uri Shanas of the University of Haifa,s ... there is a link between the higher levels of asbestos ...
... research project that develops objective and efficient methods ... requires a holistic view of the patient combining ... imaging and blood samples. "The aim ... objective indicator to diagnose Alzheimer,s disease at the ...
... Reinberg HealthDay Reporter , TUESDAY, June 14 (HealthDay ... it will require new labeling for sunscreens to identify products ... early skin aging and helping to prevent sunburn. ... A rays (UVA) and ultraviolet B (UVB) rays can be ...
... Ever since the Institute of Medicine issued its landmark report ... paid to improving patient safety in hospitals nationwide. However, ... even death, occur in private physician offices and outpatient clinics ... its kind -- researchers at Weill Cornell Medical College found ...
... the countryside, where open space is plentiful and there ... a million rural elders are far more likely to ... than their suburban counterparts, according to a new policy ... All three conditions are risk factors ...
Cached Medicine News:Health News:UF study: When singing mice choose a mate, a skillful song gets the gal 2Health News:UF study: When singing mice choose a mate, a skillful song gets the gal 3Health News:Genetic mutation linked to asbestos exposure 2Health News:Several methods for early diagnosis of Alzheimer's disease developed by European scientists 2Health News:Several methods for early diagnosis of Alzheimer's disease developed by European scientists 3Health News:Several methods for early diagnosis of Alzheimer's disease developed by European scientists 4Health News:FDA Issues New Rules on Sunscreens 2Health News:FDA Issues New Rules on Sunscreens 3Health News:JAMA study points to patient safety risks outside hospital walls 2Health News:JAMA study points to patient safety risks outside hospital walls 3Health News:Out of reach? Rural elders have highest rates of obesity, diabetes, heart disease 2
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
... Millipore has developed a range of ... match specific water quality requirements. Each ... is designed to specifically target contaminants ... HPLC, molecular biology and ICP-MS. The ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
Medicine Products: